Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has 823 institutional investors that have filed 13F reports for the period ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| FMR LLC | 31 Mar, 2026 | 14,579,166 | -1,322,983 | -8.32% | $4,823,808,693.00 |
| Capital World Investors | 31 Mar, 2026 | 10,802,348 | -5,499,424 | -33.74% | $3,573,758,048.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 10,444,908 | 44,034 | 0.42% | $3,455,906,710.00 |
| Capital Research Global Investors | 31 Mar, 2026 | 9,471,181 | 2,691,473 | 39.70% | $3,133,497,254.00 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 31 Mar, 2026 | 6,491,280 | 6,491,280 | 0.00% | $2,147,769,814.00 |
| Jpmorgan Chase & Co | 31 Mar, 2026 | 6,323,752 | 1,603,753 | 33.98% | $1,998,875,417.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 5,946,706 | 5,946,706 | 0.00% | $1,967,586,614.00 |
| T. Rowe Price Investment Management, Inc. | 31 Mar, 2026 | 5,193,324 | 2,288,337 | 78.77% | $1,718,316.00 |
| State Street Corp | 31 Mar, 2026 | 3,322,698 | 93,742 | 2.90% | $1,099,381,087.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 2,660,385 | 9,663 | 0.36% | $884,565,832.00 |
| BAILLIE GIFFORD & CO | 31 Mar, 2026 | 2,493,866 | -107,113 | -4.12% | $825,145,443.00 |
| TWO SIGMA INVESTMENTS, LP | 31 Mar, 2026 | 1,992,577 | 1,376,457 | 223.41% | $659,283,952.00 |
| WELLINGTON MANAGEMENT GROUP LLP | 31 Mar, 2026 | 1,935,925 | 306,994 | 18.85% | $640,539,505.00 |
| DODGE & COX | 31 Mar, 2026 | 1,929,253 | -35,162 | -1.79% | $638,331,940.00 |
| AMERICAN CENTURY COMPANIES INC | 31 Mar, 2026 | 1,802,363 | 317,202 | 21.36% | $596,349,775.00 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 31 Mar, 2026 | 1,432,748 | 1,432,748 | 0.00% | $474,055.00 |
| Clearbridge Investments, LLC | 31 Mar, 2026 | 1,356,036 | 759,023 | 127.14% | $448,671,479.00 |
| Orbis Allan Gray Ltd | 31 Mar, 2026 | 1,334,825 | -283,394 | -17.51% | $441,653,547.00 |
| Invesco Ltd. | 31 Mar, 2026 | 1,291,726 | -874,114 | -40.36% | $427,393,317.00 |
| MARSHALL WACE, LLP | 31 Mar, 2026 | 1,099,318 | 549,396 | 99.90% | $363,731,347.00 |